MVI is committed to exploring use of our plasmids in combinations across the prostate cancer disease spectrum.
We have run trials in early stage non-metastatic prostate cancer, during early therapy for metastatic prostate cancer, and during the later stages of castration-resistant metastatic prostate cancer.
Copyright © 2021 Madison Vaccines, Inc.
Website by Acumium
